High dose chemotherapy with peripheral blood stem cell transplantation (PBSCT) in ovarian cancer

International Journal of Gynecological Cancer

Volumn 10, Issue SUPPL. 1, 2000, Pages 53-56

  Ledermann, Jonathan A ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Dose intensity; High dose chemotherapy; Ovarian cancer; Peripheral blood stem cell transplantation

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; MELPHALAN; PACLITAXEL; PLATINUM;

ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL TIME;

EID: 0034003376     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.2000.99512.x     Document Type: Article

References (14)

1. Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Br Med Journal 1991; 303: 884-93.
2. Neijt JP, ten Bokkel Huinink WW, van der Burg MEL et al. Long Term Survival in Ovarian Cancer: Mature Data from The Netherlands Joint Study Group for Ovarian Cancer. Eur J Cancer 1991; 27: 1367-72.
3. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6.
4. Stuart G, Bertelsen K, Mangioni C et al. Updated analysis shows a highly significant improvement in overall survival (OS) for cisplatin-paclitaxel as first line treatment of advanced ovarian cancer: Mature results of the EORTC-GCCG, NOCOVA,NCIC and Scottish Intergroup trial. Proc Am Soc Clin Oncol 1998; 17: 361a (abstract).
5. Levin L. Chemotherapy Options in Ovarian Carcinoma - a Dose Intensity Perspective. London: Chapman & Hall 1995.
6. McGuire W. How many more nails to seal the coffin of dose intensity? Ann Oncol 1997; 8: 311-3.
7. Shpall E, Stemmer S, Bearman S et al. High dose chemotherapy with autologous bone marrow support for the treatment of epithelial ovarian cancer in Cancer of the Ovary. In: Hoskins WJ, Markman M, eds. Cancer of the Ovary. New York: Raven Press, 1993: 327-38.
8. Stiff PJ, Bayer R, Kerger C et al. High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients. J Clin Oncol 1997; 15: 1309-17.
9. Legros M, Dauplat J, Fleury J et al. High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: long-term results. J Clin Oncol 1997; 15: 1302-8.
10. Ledermann JA, Herd R, Maraninchi D et al. High Dose Chemotherapy in Ovarian Cancer: an Analysis of the Experience of the European Group for Blood and Marrow Transplant (EBMT) over 7 Years. Proc Am Soc Clin Oncol 1999; 18: 360a (abstract).
11. Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with haematopoetic rescue as primary treatment for metastatic breast cancer: a randomzed trial. J Clin Oncol 1995; 13: 2483-9.
12. Bezwoda W. Randomised, controlled trial of high dose chemotherapy (HD-CNVP) versus standard dose (CAF) chemotherapy for high risk, surgically treated, primary breast cancer. Proc Am Soc Clin Oncol 1999; 18: 2a (abstract).
13. Fennelly D, Schneider J, Spriggs D et al. Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/ cyclophosphamide courses. J Clin Oncol 1995; 13: 1160-6.
14. Wandt H, Birkmann J, Denzel T et al. Sequential cycles of high-dose chemotherapy with dose escalation of carboplatin with or without paclitaxel supported by G-CSF mobilized peripheral blood progenitor cells: a phase I/II study in advanced ovarian cancer. Bone Marrow Transplant 1999; 23: 763-70.